Als Biomarker To Mechanism Mapping represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
This page maps every measurable ALS biomarker to the specific mechanism it reflects and the therapeutic approaches that should move it. Each biomarker is scored for clinical utility (0-10). This page serves as a reference for interpreting clinical trial results and patient monitoring.
| Category | Biomarkers |
|---|---|
| Neurodegeneration Markers | NfL, pNfH, NfH, Neurogranin |
| Energy Metabolism | Creatine, Lactate, ATP |
| Inflammation | IL-6, TNF-alpha, CRP, YKL-40 |
| Muscle/Metabolism | Creatinine, Weight, BMI |
| Genetic | SOD1, C9orf72, FUS, TARDBP |
| Imaging | MRI, PET, DTI |
| Neurophysiology | EMG, Motor Unit Number Index |
| Functional | ALSFRS-R, FVC, SVC |
| Biomarker | Category | Mechanism(s) | Therapeutic Link | Utility Score |
|---|---|---|---|---|
| NfL (Neurofilament Light Chain) | Neurodegeneration | Axonal injury, neuronal death | All neuroprotective trials | 9.5 |
| pNfH (Phosphorylated Neurofilament Heavy) | Neurodegeneration | Axonal injury | All neuroprotective trials | 9 |
| Creatinine | Muscle/Metabolism | Muscle mass, disease progression | Metabolic therapies | 7 |
| Urinary p75ECD | Neurodegeneration | Motor neuron degeneration | All neuroprotective trials | 7.5 |
| CSF TDP-43 | Proteinopathy | TDP-43 pathology | TDP-43 targeting | 6.5 |
| IL-6 | Inflammation | Neuroinflammation | Anti-inflammatory therapies | 6 |
| YKL-40 | Inflammation | Microglial activation | Anti-inflammatory therapies | 6 |
| CRP | Inflammation | Systemic inflammation | Anti-inflammatory therapies | 5.5 |
| Lactate | Energy Metabolism | Mitochondrial dysfunction | Metabolic therapies | 6 |
| Creatine | Energy Metabolism | Energy crisis | Metabolic therapies | 6 |
| ALS Functional Rating Scale-Revised | Functional | Overall function | All trials | 10 |
| Forced Vital Capacity (FVC) | Respiratory | Respiratory function | All trials | 9 |
| Slow Vital Capacity (VC) | Respiratory | Respiratory function | All trials | 8.5 |
| Motor Unit Number Index (MUNIX) | Neurophysiology | Motor neuron loss | Neuroprotective trials | 7.5 |
What it measures: NfL is released when axons are damaged. It reflects the rate of neuronal injury.
Mechanism Link:
Expected Changes with Treatment:
Drugs that have moved NfL:
Clinical Utility: Excellent for monitoring disease progression and treatment response. Can be used as enrichment biomarker.
What it measures: Similar to NfL but more specific to motor neurons.
Mechanism Link:
Expected Changes with Treatment:
Drugs that have moved pNfH:
What it measures: Pro-inflammatory cytokine elevated in ALS.
Mechanism Link:
Expected Changes with Treatment:
Clinical Utility: Moderate. Non-specific but useful for inflammatory mechanism tracking.
What it measures: Marker of microglial activation.
Mechanism Link:
Expected Changes with Treatment:
What it measures: Muscle mass and metabolic rate.
Mechanism Link:
Expected Changes with Treatment:
What it measures: Mitochondrial function indicator.
Mechanism Link:
Expected Changes with Treatment:
| Biomarker | Glutamate | Oxidative Stress | Inflammation | Mitochondria | Gene Therapy | Metabolism |
|---|---|---|---|---|---|---|
| NfL | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| pNfH | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| IL-6 | ↓ | ↓ | ↓ | ↓ | — | ↓ |
| YKL-40 | — | — | ↓ | — | — | — |
| Creatinine | — | — | — | ↑ | — | ↑ |
| Lactate | — | ↓ | — | ↓ | — | ↓ |
| ALSFRS-R | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
Legend: ↓ Expected decrease with effective treatment, ↑ Expected increase/improvement
| Criterion | Weight | Description |
|---|---|---|
| Specificity | 25% | How specific is this to ALS/ALS mechanisms? |
| Sensitivity | 25% | How early can it detect disease? |
| Response to treatment | 25% | Does it change with effective treatment? |
| Clinical availability | 15% | How easy to measure in clinic? |
| Validation | 10% | How well validated in ALS? |
| Rank | Biomarker | Specificity | Sensitivity | Treatment Response | Availability | Validation | Total |
|---|---|---|---|---|---|---|---|
| 1 | ALSFRS-R | 7 | 8 | 9 | 10 | 10 | 9.0 |
| 2 | NfL | 9 | 9 | 9 | 8 | 9 | 8.8 |
| 3 | FVC | 8 | 8 | 8 | 9 | 9 | 8.3 |
| 4 | pNfH | 8 | 8 | 8 | 8 | 8 | 8.0 |
| 5 | Urinary p75ECD | 7 | 7 | 7 | 8 | 7 | 7.2 |
| 6 | MUNIX | 8 | 7 | 7 | 6 | 7 | 7.1 |
| 7 | Creatinine | 6 | 6 | 6 | 9 | 8 | 6.8 |
| 8 | YKL-40 | 6 | 5 | 6 | 7 | 6 | 6.0 |
The study of Als Biomarker To Mechanism Mapping has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 34%